Smith & Nephew Delivers Robust First Half, Flexes Financial Muscle with Buyback
Medical technology stalwart Smith & Nephew (LSE: SN, NYSE: SNN) has served up a set of H1 2025 results that positively hum with operational momentum. The numbers tell a compelling story: accelerating growth, expanding margins, and cash generation that’s shifted decisively into higher gear. Crucially, this performance isn’t just a flash in the pan – it’s underpinned by strategic execution and innovation that’s starting to yield tangible results. Let’s dissect the figures and see why management felt confident enough to greenlight a hefty $500 million share buyback.
The Headline Numbers: Growth, Profit & Cash Converge
For the six months ended 28 June 2025, Smith & Nephew reported:
- Revenue: $2,961 million, reflecting a solid 5.0% underlying growth (4.7% reported).
- Trading Profit: Up a robust 11.2% to $523 million.
- Trading Profit Margin: Expanded by a full percentage point to 17.7%.
- Operating Profit: Surged 30.6% to $429 million.
- Free Cash Flow (FCF): The standout performer – exploding to $244 million from just $39 million in H1 2024. Trading cash conversion jumped to 93%.
- EPSA (Adjusted EPS): Increased 14.1% to 42.9 cents.
The second quarter saw a notable acceleration, with underlying revenue growth hitting 6.7% (7.8% reported). This sequential improvement wasn’t confined to one area; it was broad-based across all three business units and all regions.
Business Unit Breakdown: Where the Growth Came From
Digging into the segments reveals the engines driving this performance:
Orthopaedics (Q2 Underlying Growth: 5.0%)
A welcome return to form, particularly in Reconstruction. Global Reconstruction improved sequentially, with US Reconstruction showing a clear uptick (2.0% growth vs 1.3% in Q1). Hip implants shone in the US, driven by the new CATALYSTEM Primary Hip System. Robotics (CORI Surgical System) and Trauma also contributed strongly. The unit’s trading profit margin leapt 230bps, showcasing the impact of operational improvements.
Sports Medicine & ENT (Q2 Underlying Growth: 5.7%)
Excluding China (impacted by Volume-Based Procurement), underlying growth was a much stronger 10.2%. Sports Medicine Joint Repair led the charge (8.4% growth), fuelled by the REGENETEN Bioinductive Implant and recent launches like the Q-FIX KNOTLESS Anchor. ENT delivered steady growth. Margin was pressured by China VBP but remains healthy overall.
Advanced Wound Management (Q2 Underlying Growth: 10.2%)
The star performer. Double-digit growth was driven by a rebound in Bioactives (like SANTYL) and stellar performances in Devices (NPWT portfolio, LEAF monitoring) and Bioactives (skin substitutes). Securing a significant $75 million US Department of Defense contract for RENASYS TOUCH NPWT was a major win. Margins expanded impressively by 160bps.
Geographical Spread: Established Markets Power Ahead
The regional story reinforces the strength:
- Established Markets: Underlying growth of 8.2% in Q2. The US was particularly strong (8.7% underlying), while Other Established Markets (Europe, Japan, etc.) grew 7.4%.
- Emerging Markets: A slight underlying decline of 0.2%, but crucially, excluding China, underlying growth was a robust 12.2%. China headwinds are easing as distributor destocking nears completion.
The $500 Million Flex: Share Buyback & Dividend Hike
This is where confidence meets capital allocation. That surge in free cash flow ($244m!) isn’t just sitting idle. Smith & Nephew announced:
- $500 Million Share Buyback: To be executed in the second half of 2025. This is a significant return of capital, explicitly stated to be done while maintaining leverage targets and without compromising growth plans. It’s a powerful signal of financial strength and belief in the ongoing transformation.
- Interim Dividend Increase: Up 4.2% to 15.0 cents per share, demonstrating a commitment to the progressive dividend policy.
CEO Deepak Nath nailed it: “The transformation of Smith+Nephew is starting to deliver substantial value.” This buyback is tangible proof.
Innovation Pipeline: Fuel for Future Growth
New products aren’t just launches; they’re growth vectors. Products launched in the last five years contributed a hefty three-quarters of H1 revenue growth. Highlights include:
- Orthopaedics: LEGION medial stabilised inserts, TRIGEN MAX Tibia Nailing, CORIOGRAPH Pre-Op Planning (expanding CORI’s capabilities).
- Sports Medicine: Expanded indications for REGENETEN, Q-FIX KNOTLESS Anchor.
- AWM: ALLEVYN Ag+ SURGICAL launch in the US.
Supporting clinical evidence is also robust, bolstering adoption of key platforms like OXINIUM bearings and JOURNEY II knees with robotics.
Outlook: Steady As She Goes (Despite Headwinds)
Management reaffirmed full-year 2025 guidance, a sign of underlying confidence:
- Underlying Revenue Growth: Around 5.0%.
- Trading Profit Margin: Expected between 19.0% and 20.0%.
This outlook factors in known headwinds: $15-$20 million from tariffs and the anticipated 2026 impact of proposed Medicare changes for skin substitutes in the US (AWM). The expectation is for further margin expansion beyond 2025.
The Takeaway: Execution Translates to Value
Smith & Nephew’s H1 2025 report card is undeniably strong. It’s not just about hitting numbers; it’s about the *how*. The acceleration in Q2, the margin expansion (especially in Orthopaedics and AWM), and the dramatic cash flow improvement all point to Nath’s 12-Point Plan bearing fruit. Operational discipline and a focus on high-impact innovation are driving a tangible transformation.
The $500 million buyback is more than just a reward for shareholders; it’s a bold statement. It says the company is generating excess cash, has confidence in its future cash flows, and sees its shares as an attractive investment. While challenges remain (tariffs, China dynamics, reimbursement changes), Smith & Nephew appears firmly on track, demonstrating that in medtech, consistent execution and smart capital allocation can indeed start to deliver “substantial value.”
